Induced pluripotent stem cell (iPSC)-derived immortalized megakaryocyte cell lines (imMKCLs) from voluntary blood component donors with specific HLA haplotypes towards platelet products in transfusion therapy.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000015345

Enrollment

Registered

2014-11-01

Start date

2014-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thrombocytopenia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ?Voluntary, non-remunerated, healthy blood component donors ?Homozygotes of HLA-A, HLA-B, and HLA-C ?Blood type O ?Individuals capable of giving voluntary, informed consent in writing

Exclusion criteria

Exclusion criteria: ?The following viral infection: Hepatic Virus B Hepatic Virus C Human Immunodeficiency Virus Human T-cell leukemia virus Human parvovirus B19 Cytomegalovirus ?The following microbial infection: Treponema pallidum West Nile Virus Chlamydiaceae Genus Neisseria Mycobacterium Malaria parasites(Plasmodium spp.) Babesia Trypanosoma cruzi Leishmania Trypanosoma brucei ?Malignant neoplasm ?Transmissible spongiform encephalopathy (including suspected case), Dementia or cognitive impairment, Stroke, Seizure ?The following conditions: Particular or genetic/hereditary disorders Severe or uncontrolled metabolic or endocrinal disorders Connective tissue diseases Severe or uncontrolled hematologic diseases Severe or uncontrolled hepatic disorders ?Enrolling related studies of generating iPSC banks

Design outcomes

Primary

Measure	Time frame
In vitro safety and functional studies by platelets generated from human iPSC-derived immortalized megakaryocyte cell lines	—

Countries

Japan

Outcome results